In this final segment, Joseph Sullivan, MD, outlines the rationale, design, and key considerations behind the phase 3 EMPEROR trial, which aims to confirm zorevunersen’s efficacy and potential disease-modifying effects in Dravet syndrome. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.
In this episode, epilepsy expert Joseph Sullivan, MD, explains how zorevunersen achieved meaningful seizure and developmental improvements even in patients already receiving highly effective antiseizure medications. [WATCH TIME: 3 minutes]
Salvia BioElectronics’ PRIMUS system, currently being assessed in a phase 3 study, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.
Avi Singh Gandh, MD, neurology resident at Emory University School of Medicine, reflected on how modern neurology can interpret the Salem Witch Trials.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rebecca Edelmayer, PhD. [LISTEN TIME: 14 minutes]
A groundbreaking trial compares nipocalimab and efgartigimod for treating generalized myasthenia gravis, promising new insights for patient care.
A perspective model aimed noted that introducing efgartigimod alfa for patients with chronic inflammatory demyelinating polyneuropathy incurs more expected costs.
Epilepsy expert Joseph Sullivan, MD, detailed zorevunersen’s effects on adaptive behavior and communication skills, emphasizing improvements on the Vineland-3 scale that extend beyond seizure control. [WATCH TIME: 5 minutes]
Patients with generalized myasthenia gravis reported a positive experience with rozanolixizumab self-administration, with a preference for the manual push method.
An open-label extension trial testing the efficacy of nipocalimab in patients transitioning from placebo revealed continued improvement in MG-Activities of Daily Living scores over a long-term period.
Andrew Russman, DO, medical director of Cleveland Clinic’s Comprehensive Stroke Center, shared insights on stroke awareness, prevention, and the growing importance of heart-brain collaboration in care.
Data showed that efgartigimod led to greater improvements in disease activity compared with placebo in idiopathic inflammatory myopathy, and improvements in seronegative myasthenia gravis.
In this episode, Joseph Sullivan, MD, reviews zorevunersen’s long-term safety profile, including cerebrospinal fluid protein changes, procedural effects, and the absence of clinically significant adverse events. [WATCH TIME: 3 minutes]
Obexelimab shows promising results in reducing lesions in relapsing multiple sclerosis, highlighting its potential as a new treatment for autoimmune diseases.
Amid World Stroke Day, neurosurgeon Evan Luther, MD, discussed the PICASSO trial’s effort to clarify the role of acute carotid stenting during mechanical thrombectomy for tandem occlusions in ischemic stroke.
An analysis of the first 110 patients screened for the ARISE study showed that an independent adjudication committee confirmed the diagnosis of CIDP in nearly 3-quarters of cases.
The chief science officer at the American Heart Association discusses its priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day 2025.
A post-hoc analysis study revealed apomorphine sublingual film was efficacious over a long term period across various age ranges, including elders, with Parkinson disease.
Epilepsy expert Joseph Sullivan, MD, reviews 36-month results from the zorevunersen program, highlighting durable seizure reduction and sustained efficacy following dose optimization. [WATCH TIME: 4 minutes]
The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.
Exenatide shows effects on brain metabolism in Parkinson disease but fails to provide clinical benefits, as recent trials reveal mixed results.
The professor of clinical neuroscience at Newcastle University discussed selecting appropriate and representative patient populations across different phases of clinical trials for Parkinson disease. [WATCH TIME: 5 minutes]
The assistant professor of neurology at Northwestern University shared important clinical insights for early-career clinicians entering neuroimmunology, emphasizing best practices in recognizing, testing, and confirming NMOSD. [WATCH TIME: 3 minutes]
Riley Bove, MD, an associate professor of neurology at the University of California, San Francisco, discussed phase 4 findings from the MINORE and SOPRANINO studies that examined ocrelizumab exposure during pregnancy and lactation in women with MS.
Mark Forman, MD, PhD, chief medical officer at Ventyx Biosciences, discussed promising early-stage data of VTX3232, an NLRP3 inflammasome in development for early-stage Parkinson disease.
Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.
Here's some of what is coming soon to NeurologyLive® this week.
In a recent study of patients with testicular germ cell tumors, most exhibited paraneoplastic neurologic syndromes proceeding with their cancer diagnosis, often associated with specific neural autoantibodies.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on genetics for epilepsy.
